penciclovir - Profile

What are the generic sources for penciclovir and what is the scope of freedom to operate?

Penciclovir is the generic ingredient in two branded drugs marketed by Mylan, Amneal, Padagis Israel, Teva Pharms Usa, and Torrent, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for penciclovir

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5

US Patents and Regulatory Information for penciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996	AB	RX	Yes	Yes
Amneal	PENCICLOVIR	penciclovir	CREAM;TOPICAL	214100-001	Aug 22, 2025	AB	RX	No	No
Padagis Israel	PENCICLOVIR	penciclovir	CREAM;TOPICAL	212368-001	Sep 27, 2024	AB	RX	No	No
Teva Pharms Usa	PENCICLOVIR	penciclovir	CREAM;TOPICAL	212710-001	Nov 9, 2022	AB	RX	No	No
Torrent	PENCICLOVIR	penciclovir	CREAM;TOPICAL	216981-001	Aug 7, 2023	BX	RX	No	No

Expired US Patents for penciclovir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996
Mylan	DENAVIR	penciclovir	CREAM;TOPICAL	020629-001	Sep 24, 1996

Investment scenario and fundamentals analysis for penciclovir

Last updated: February 9, 2026

Overview

Penciclovir is an antiviral drug primarily used topically for herpes labialis (cold sores). It is marketed under the brand name Denavir or Vivorax, depending on the region. As a nucleoside analog, penciclovir inhibits viral DNA polymerase, reducing herpes virus replication.

Market Size and Growth Potential

• Global cold sore treatment market valued at approximately $650 million in 2022.[1]
• CAGR estimated at 4.2% from 2023-2030, driven by increasing incidence of herpes simplex virus (HSV) infections, aging populations, and rising demand for over-the-counter (OTC) remedies.
• Penciclovir's niche lies in prescription topical formulations. The total addressable market (TAM) is limited compared to systemic antivirals but stable due to recurrent herpes outbreaks.

Competitive Landscape

• Main competitors include acyclovir, valacyclovir, famciclovir, and newer agents with improved efficacy or dosing.
• Penciclovir's topical formulations face competition from OTC products like docosanol (Abreva). Prescription products have less competition but are limited by side effect profiles and patient preference.
• Patent status: Penciclovir patents have expired or are nearing expiry in key markets, opening opportunities for generic formulations but reducing exclusivity premiums.

Regulatory and Patent Landscape

• Penciclovir topical formulation approvals date back to the 1980s (US NDA approval in 1986). No recent major regulatory hurdles.
• Patent expirations: Several key patents expired between 2010-2020, leading to generic entry.
• Opportunities exist in reformulations, combination therapies, or new delivery systems (e.g., nanoparticles, patches) to extend patent life.

Development and R&D Outlook

• No current clinical trials for new indications; focus remains on formulation improvements.
• Potential for reformulation into longer-acting or faster-absorbing systems.
• Research interest in extending use to other herpes infections or prophylaxis remains limited.

Financial Metrics and Investment Considerations

• Brand sales: Estimated at $150-200 million annually in the US, with European markets contributing an additional $100 million.
• Margin profile: Topical antivirals have low R&D costs but modest profit margins due to generic competition.
• Investment risk: High risk of price erosion post-patent expiry; minimal upside without new formulations or indications.
• Licensing and partnering opportunities: Some pharmas seek licensing rights for innovative formulations in emerging markets or for combination therapies.

Emerging Opportunities and Risks

• Emerging markets present growth opportunities due to increased healthcare access.
• Risks include patent cliff effects, OTC market competition, and potential shifts toward systemic antivirals with longer duration.
• Investment in reformulation technologies offers potential for premium pricing but requires R&D investment and regulatory approval.

Summary

Investing in penciclovir involves balancing its stable market for topical herpes treatment against patent expirations and competition from generics and OTC products. Opportunities exist in reformulation and new delivery methods, but the overall outlook depends on innovation pace and market penetration strategies.

---

Key Takeaways

• The penciclovir market is mature with modest growth driven by herpes simplex virus prevalence.
• Patent expiries have exposed the market to generics, constraining pricing.
• R&D efforts focus on reformulation, with limited pipeline activity for new indications.
• Competitive positioning hinges on formulation innovation and regional licensing.
• Risks include pricing erosion, OTC competition, and limited future upside without new product development.

---

FAQs

1. What is the main therapeutic use of penciclovir?
It is used for treating cold sores caused by herpes simplex virus type 1 (HSV-1).

2. How does penciclovir compare to acyclovir?
Penciclovir has similar antiviral activity but is typically formulated as a topical cream, whereas acyclovir is available as oral, injectable, or topical forms. Its topical application offers targeted treatment with fewer systemic side effects.

3. What factors influence penciclovir’s market price?
Patent status, generic availability, formulation innovations, regional demand, and OTC vs. prescription classification.

4. Are there new indications for penciclovir under development?
Currently, no significant new clinical indications are being pursued.

5. What strategic approaches could extend penciclovir’s commercial viability?
Development of controlled-release formulations, combination therapies, or new delivery systems such as patches could provide premium pricing and prolong market exclusivity.

---

Sources

[1] Grand View Research, "Cold Sore Treatment Market," 2022.